According to the FDA, there are two new cases of brain inflammation that have been seen in patients who are being treated with the lymphoma drug brentuximab vedotin (Adcetris). The brain inflammation is considered life-threatening.
After taking the drug, there are currently three patients who have been diagnosed with progressive multifocal leukoencephalopathy (PML).
Symptoms for (PML) include headache, memory loss, vision problems, loss of language ability, and weakness in the arms and legs.
The FDA has now created a new warning on the drug's box that lets consumers see the new dangerous risk associated with it.